[go: up one dir, main page]

EP3177649A1 - Anticorps anti-pd-l1 - Google Patents

Anticorps anti-pd-l1

Info

Publication number
EP3177649A1
EP3177649A1 EP15829791.1A EP15829791A EP3177649A1 EP 3177649 A1 EP3177649 A1 EP 3177649A1 EP 15829791 A EP15829791 A EP 15829791A EP 3177649 A1 EP3177649 A1 EP 3177649A1
Authority
EP
European Patent Office
Prior art keywords
antibody
homology
fragment
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15829791.1A
Other languages
German (de)
English (en)
Other versions
EP3177649B1 (fr
EP3177649A4 (fr
Inventor
Ziyong Sun
Jiping Zha
Junzhuan Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollomics Inc
Original Assignee
CB Therapeutics Inc Cayman Island
CB Therapeutics Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CB Therapeutics Inc Cayman Island, CB Therapeutics Inc USA filed Critical CB Therapeutics Inc Cayman Island
Publication of EP3177649A1 publication Critical patent/EP3177649A1/fr
Publication of EP3177649A4 publication Critical patent/EP3177649A4/fr
Application granted granted Critical
Publication of EP3177649B1 publication Critical patent/EP3177649B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to antibodies and antigen-binding fragments thereof that bind to PD-Ll , and to methods of using such antibodies and antigen-binding fragments.
  • PD-Ll is a ligand of programmed death receptor 1 (PD-1).
  • PD-1 is primarily expressed on lymphocytes and has two ligands, PD-Ll and PD-L2.
  • PD-L2 is not as common as PD-Ll .
  • PD-Ll is also known as cluster of differentiation 274 (CD274) or B7 ho mo log 1 (B7-H1) and is a 40kDa type 1 transmembrane protein which is encoded by the CD274 gene.
  • Both PD-Ll and PD-1 belong to immunoglobulin superfamily and consist of two extracellular Ig domains, an N-terminal V domain, and a C-terminal constant domain.
  • PD-Ll to programmed death 1 (PD-1) and B7-1 (CD80) is on the IgV-like domain (Lin et al. (2008) PNAS 105:3011-3016). While PD-Ll contains a conserved short intracellular tail (about 30 amino acids), PD-1 contains two cytoplasmic tyrosine-based signaling motifs, an immunoreceptor tyrosine -based inhibition motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM).
  • ITIM immunoreceptor tyrosine -based inhibition motif
  • ITDM immunoreceptor tyrosine-based switch motif
  • PD-1 recruits the tyrosine phosphatase SHP-2 to the ITSM motif within its cytoplasmic tail, leading to the dephosphorylation of effector molecules such as CD3 Zeta, PKC theta and ZAP70 that are involved in the CD3 T cell signaling cascade (Freeman et al. (2000) J Exp Med 192: 1027-34; Latchman, et. al. (2001) Nat Immunol 2:261-8; Carter et al. (2002) Eur J Immunol 32:634-43).
  • effector molecules such as CD3 Zeta, PKC theta and ZAP70 that are involved in the CD3 T cell signaling cascade
  • PD-Ll is not only widely distributed on leukocytes and nonhematopoietic cells in lymphoid and nonlymphoid tissues, but also in various cancer cells. Clinical data suggest that high tumor expression of PD-Ll is associated with increased tumor aggressiveness and poorer prognosis.
  • the formation of PD-l/PD-Ll complex transmits an inhibitory signal and negatively regulates T cell immune responses; it inhibits TCR-mediated T cell activation, cytokine production and T cell proliferation (Fife et al. (201 1) Nature Immunology 10: 1 185-1 193); induces exhaustion or anergy among cognate antigen-specific T cells (Hofmeyer et al.
  • the present invention provides antibodies and antigen-binding fragments thereof that bind to programmed death- 1 ligand 1 (PD-Ll).
  • the antibodies and antigen-binding fragments thereof bind to human PD-Ll .
  • the antibodies and antigen-binding fragments thereof bind to PD-Ll and block binding of PD-1 and/or CD80 to PD-Ll .
  • the anti-PD-Ll antibodies and fragments thereof bind to PD-Ll and disrupt the PD-Ll/PD-1 or PD-L1/CD80 pathway.
  • the antibody or fragment thereof is a murine antibody, a chimeric antibody, a human antibody or a humanized antibody.
  • the anti-PD-Ll antibody or fragment thereof is a monoclonal antibody, scFv, Fab fragment, Fab' fragment, F(ab)' fragment, bispecific antibody, immuno conjugate, or a combination thereof
  • the present invention provides an isolated antibody or fragment thereof comprising one or more CDRs selected from the group consisting of SEQ ID NOs: 81- 140.
  • the antibody or fragment thereof comprises a heavy chain CDR1 sequence having at least 80% homology, at least 81% homology, at least 82% homology, at least 83% homology, at least 84% homology, at least 85% homology, at least 86% homology, at least 87% homology, at least 88% homology, at least 89% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 81 , 87, 93, 99, 105, 1 1 1 , 1 17, 123, 129, and 135.
  • the antibody or fragment thereof comprises a heavy chain CDR2 sequence having at least 80% homology, at least 81% homology, at least 82% homology, at least 83% homology, at least 84% homology, at least 85% homology, at least 86% homology, at least 87% homology, at least 88% homology, at least 89% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 82, 88, 94, 100, 106, 1 12, 1 18, 124, 130, and 136.
  • the antibody or fragment thereof comprises a heavy chain CDR3 sequence having at least 80% homology, at least 81% homology, at least 82% homology, at least 83% homology, at least 84% homology, at least 85% homology, at least 86% homology, at least 87% homology, at least 88% homology, at least 89% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 83, 89, 95, 101 , 107, 1 13, 1 19, 125, 131 , and 137.
  • the antibody or fragment thereof comprises a light chain CDR1 sequence having at least 80% homology, at least 81% homology, at least 82% homology, at least 83% homology, at least 84% homology, at least 85% homology, at least 86% homology, at least 87% homology, at least 88% homology, at least 89% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 84, 90, 96, 102, 108, 1 14, 120, 126, 132, and 138.
  • the antibody or fragment thereof comprises a light chain CDR2 sequence having at least 80% homology, at least 81% homology, at least 82% homology, at least 83% homology, at least 84% homology, at least 85% homology, at least 86% homology, at least 87% homology, at least 88% homology, at least 89% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 85, 91 , 97, 103, 109, 1 15, 121 , 127, 133, and 139.
  • the antibody or fragment thereof comprises a light chain CDR3 sequence having at least 80% homology, at least 81% homology, at least 82% homology, at least 83% homology, at least 84% homology, at least 85% homology, at least 86% homology, at least 87% homology, at least 88% homology, at least 89% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 86, 92, 98, 104, 1 10, 1 16, 122, 128, 134, and 140.
  • the antibody or fragment thereof comprises a heavy chain CDR1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 81 , 87, 93, 99, 105, 1 1 1 , 1 17, 123, 129, and 135; a heavy chain CDR2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 82, 88, 94, 100, 106, 1 12, 1 18, 124, 130, and 136; a heavy chain CDR3 consisting of an amino acid sequences selected from the group consisting of SEQ ID NOs: 83, 89, 95, 101 , 107, 1 13, 1 19, 125, 131 , and 137; a light chain CDR1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 84, 90, 96, 102, 108, 1 14, 120, 126, 132, and 138; a light chain CDR2 consisting of an amino acid sequence selected from the group consisting of SEQ
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 81 , 82, and 83, respectively; and a light chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology,
  • the antibody or antibody fragment thereof comprises a heavy chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 81 , 82, and 83, respectively, and a light chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 84, 85, and 86, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 87, 88, and 89, respectively; and a light chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or
  • the antibody or antibody fragment thereof comprises a heavy chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 87, 88, and 89, respectively, and a light chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 90, 91 , and 92, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 93, 94, and 95, respectively; and a light chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least
  • the antibody or antibody fragment thereof comprises a heavy chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 93, 94, and 95, respectively, and a light chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 96, 97, and 98, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 99, 100, and 101 , respectively; and a light chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least
  • the antibody or antibody fragment thereof comprises a heavy chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 99, 100, and 101 , respectively, and a light chain CDRl , CDR2, and CDR3 according to SEQ ID NOs: 102, 103, and 104, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDRl , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 105, 106, and 107, respectively; and a light chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or
  • the antibody or antibody fragment thereof comprises a heavy chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 105, 106, and 107, respectively, and a light chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 108, 109, and 1 10, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 1 1 1 , 1 12, and 1 13, respectively; and a light chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or
  • the antibody or antibody fragment thereof comprises a heavy chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 1 1 1 , 1 12, and 1 13, respectively, and a light chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 1 14, 1 15, and 1 16, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 1 17, 1 18, and 1 19, respectively; and a light chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid
  • the antibody or antibody fragment thereof comprises a heavy chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 1 17, 1 18, and 1 19, respectively, and a light chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 120, 121 , and 122, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 123, 124, and 125, respectively; and a light chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or
  • the antibody or antibody fragment thereof comprises a heavy chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 123, 124, and 125, respectively, and a light chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 126, 127, and 128, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 129, 130, and 131 , respectively; and a light chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or
  • the antibody or antibody fragment thereof comprises a heavy chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 129, 130, and 131 , respectively, and a light chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 132, 133, and 134, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence according to SEQ ID NOs: 135, 136, and 137, respectively; and a light chain CDR1 , CDR2, and CDR3 comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least
  • the antibody or antibody fragment thereof comprises a heavy chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 135, 136, and 137, respectively, and a light chain CDR1 , CDR2, and CDR3 according to SEQ ID NOs: 138, 139, and 140, respectively.
  • the antibody or fragment thereof binds PD-L1 and comprises a heavy chain variable region comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46; and a light chain variable region comprising an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group
  • the isolated antibody or fragment thereof binds PD-L1 and comprises a heavy chain variable region comprising, consisting essentially of, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46; and a light chain variable region comprising, consisting essentially of, or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
  • the invention provides anti-PD-Ll antibodies that comprise a variable heavy chain of an antibody selected from the group consisting of 13C5, 5G9, 5G1 1 , 8C6, 7B4, 4D1 , 4A8, 8H4, 8H3, and 15F1 and a variable light chain of an antibody selected from the group consisting of 13C5, 5G9, 5G1 1 , 8C6, 7B4, 4D1 , 4A8, 8H4, 8H3, and 15F1.
  • the invention provides an antibody or fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 and a light chain variable region comprising SEQ ID NO: 4; a heavy chain variable region comprising SEQ ID NO: 6 and a light chain variable region comprising SEQ ID NO: 8; a heavy chain variable region comprising SEQ ID NO: 10 and a light chain variable region comprising SEQ ID NO: 12; a heavy chain variable region comprising SEQ ID NO: 14 and a light chain variable region comprising SEQ ID NO: 16; a heavy chain variable region comprising SEQ ID NO: 18 and a light chain variable region comprising SEQ ID NO: 20; a heavy chain variable region comprising SEQ ID NO: 22 and a light chain variable region comprising SEQ ID NO: 24; a heavy chain variable region comprising SEQ ID NO: 26 and a light chain variable region comprising SEQ ID NO: 28; a heavy chain variable region comprising SEQ ID NO: 30 and a light chain variable region comprising SEQ ID NO: 32
  • the present invention provides a chimeric anti-PD-Ll antibody, wherein the antibody comprises a heavy chain having an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 54, 58, 60, 64, and 66; and a light chain having an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consist
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a heavy chain variable region having an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 42 and 46.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a light chain variable region having an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91 % homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 44 and 48.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a heavy chain variable region having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to SEQ ID NO: 42 and a light chain variable region having least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to SEQ ID NO: 44.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a heavy chain variable region having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to SEQ ID NO: 46 and a light chain variable region having least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to SEQ ID NO: 48.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a full heavy chain having an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 70, 72, 76, and 78.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a full light chain having an amino acid sequence having at least 80% homology, at least 85% homology, at least 90% homology, at least 91% homology, at least 92% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, or at least 99% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 74 and 80.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a heavy chain according to SEQ ID NO: 70 and a light chain according to SEQ ID NO: 74.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a heavy chain according to SEQ ID NO: 72 and a light chain according to SEQ ID NO: 74.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a heavy chain according to SEQ ID NO: 76 and a light chain according to SEQ ID NO: 80.
  • the present invention provides a humanized anti-PD-Ll antibody, wherein the antibody comprises a heavy chain according to SEQ ID NO: 78 and a light chain according to SEQ ID NO: 80.
  • the present invention provides anti-PD-Ll antibodies or fragments thereof that bind to the same epitope on PD-Ll as any of the exemplary antibodies provided herein. In one embodiment, the antibodies or fragments thereof compete with any of the exemplary antibodies provided herein for binding to PD-Ll . Binding to PD-Ll may be measured by ELISA, flow cytometry, surface plasmon resonance (SPR) assay, or any other method known in the art. [0034] In one embodiment, the present invention provides anti-PD-Ll antibodies and fragments thereof that bind to PD-L1 with a binding affinity kD of about 10 nM to about 0.01 nM.
  • the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of from about 10 nM to about 0.05 nM. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of from about 8 nM to about 0.1 nM. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of from about 5nM to about 0.2 nM.
  • the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 10 nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 6nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 4nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 2 nM or less.
  • the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about InM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.75 nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.5 nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.25 nM or less.
  • the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.2 nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.15 nM or less. In a further embodiment, the anti- PD-L1 antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.1 nM or less. In a further embodiment, the anti- PD-L1 antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.075 nM or less.
  • the anti- PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.05 nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-L1 with a binding affinity kD of about 0.025 nM or less. In a further embodiment, the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-Ll with a binding affinity kD of about 0.02 nM or less. In a further embodiment, the anti- PD-Ll antibodies and fragments thereof provided herein bind to PD-Ll with a binding affinity kD of about 0.015 nM or less.
  • the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-Ll with a binding affinity kD of about 0.01 nM or less. In one embodiment, the binding affinity kD of the anti-PD-Ll antibodies and fragments provided herein is measured by Biacore assay.
  • the anti PD-Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 1 ng/mL to about 2000 ng/mL. In a further embodiment, the anti PD-Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 1 ng/mL to about 1500 ng/mL. In a further embodiment, the anti PD- Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 1 ng/mL to about 1000 ng/mL.
  • the anti PD-Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 2 ng/mL to about 500 ng/mL. In a further embodiment, the anti PD-Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 2 ng/mL to about 250 ng/mL. In a further embodiment, the anti PD-Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 5 ng/mL to about 200 ng/mL.
  • the anti PD-Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 5 ng/mL to about 50 ng/mL. In one embodiment, the anti PD-Ll antibodies and fragments thereof provided herein have a binding EC50 for PD-Ll of about 500 ng/mL or less, about 400 ng/mL or less, about 300 ng/mL or less, about 250 ng/mL or less, about 200 ng/mL or less, about 150 ng/mL or less, about 100 ng/mL or less, about 75 ng/mL or less, about 60 ng/mL or less, about 50 ng/mL or less, about 40 ng/mL or less, or about 30 ng/mL or less. In one embodiment, the EC50 of the anti-PD- Ll antibodies and fragments provided herein is measured by ELISA or FACS.
  • the anti PD-Ll antibodies and fragments thereof provided herein inhibit PDLl/PD-1 binding with an IC50 of about of about 1 ng/mL to about 1500 ng/mL. In a further embodiment, the anti PD-Ll antibodies and fragments thereof provided herein inhibit PDLl/PD-1 binding with an IC50 of about 2 ng/mL to about 1200 ng/mL. In a further embodiment, the anti PD-Ll antibodies and fragments thereof provided herein inhibit PDL1/PD- 1 binding with an IC50 of about 5 ng/mL to about 500 ng/mL.
  • the anti PD-L1 antibodies and fragments thereof provided herein inhibit PDLl/PD-1 binding with an IC50 of about 5 ng/mL to about 100 ng/mL. In a further embodiment, the anti PD-L1 antibodies and fragments thereof provided herein inhibit PDLl/PD-1 binding with an IC50 of about 10 ng/mL to about 50 ng/mL.
  • the anti PD-L1 antibodies and fragments thereof provided herein inhibit PDLl/PD-1 binding with an IC50 of about 1200 ng/mL or less, about 1000 ng/mL or less, about 800 ng/mL or less, about 400 ng/mL or less, about 300 ng/mL or less, about 250 ng/mL or less, about 200 ng/mL or less, about 150 ng/mL or less, about 100 ng/mL or less, about 75 ng/mL or less, about 60 ng/mL or less, about 50 ng/mL or less, about 40 ng/mL or less, about 30 ng/mL or less, about 20 ng/mL or less, or about 10 ng/mL or less.
  • the IC50 of the anti-PD-Ll antibodies and fragments provided herein is measured by ELISA or FACS.
  • the anti-PD-Ll antibody provided herein is a humanized antibody having a heavy chain variable region amino acid sequence according to SEQ ID NO: 42 and a light chain variable region amino acid according to SEQ ID NO: 44; or having a heavy chain variable region amino acid sequence according to SEQ ID NO: 46 and a light chain variable region amino acid sequence according to SEQ ID NO: 48; wherein the anti-PD-Ll antibody has a PD-L1 binding EC50 of about 200ng/ml or less or about 150 ng/mL or less or about 100 ng/mL or less or about 80 ng/ml or less or about 60 ng/mL or less or about 50 ng/mL or less, as measured by ELISA or FACS.
  • the anti-PD-Ll antibody provided herein is a humanized antibody having a heavy chain variable region amino acid sequence according to SEQ ID NO: 42 and a light chain variable region amino acid according to SEQ ID NO: 44; or having a heavy chain variable region amino acid sequence according to SEQ ID NO: 46 and a light chain variable region amino acid sequence according to SEQ ID NO: 48; wherein the anti- PD-Ll antibody has a PDLl/PD- 1 blockage IC50 of about 1200 ng/mL or less, or about 1000 ng/mL or less, or about 800 ng/mL or less, or about 600 ng/mL or less, or about 500 ng/mL or less, or about 400 ng/mL or less, or about 300 ng/mL or less, or about 200 ng/mL or less, or about 100 ng/mL or less, or about 60 ng/mL or less, or about 30 ng/mL or less, or about 25 ng/mL or less, or
  • the anti-PD-Ll antibody provided herein is a humanized antibody having a heavy chain variable region amino acid sequence according to SEQ ID NO: 42 and a light chain variable region amino acid according to SEQ ID NO: 44; or having a heavy chain variable region amino acid sequence according to SEQ ID NO: 46 and a light chain variable region amino acid sequence according to SEQ ID NO: 48; wherein the anti-PD-Ll antibody has a binding affinity kD for PD-Ll of about 10 nM or less, or about 5 nM or less, or about 2nM or less, or about 1 nM or less, or about 0.5 nM or less, or about 0.1 nM or less, or about 0.05nM or less, as measured by Biacore assay.
  • the humanized anti- PD-Ll antibody has a binding affinity kD for PD-Ll of about 2 nM. In another embodiment, the humanized anti-PD-Ll antibody has a binding affinity kD for PD-Ll of about 1 nM. In another embodiment, the humanized anti-PD-Ll antibody has a binding affinity kD for PD-Ll of about 0.5 nM. In another embodiment, the humanized anti-PD-Ll antibody has a binding affinity kD for PD-Ll of about 0.1 nM.
  • the anti-PD-Ll antibodies and fragments thereof provided herein bind to PD-Ll , disrupting the PD-l/PD-Ll interaction and resulting in an increase in T cell activation.
  • the antibodies and fragments thereof bind PD-Ll and result in an increase in T cell proliferation and/or cytokine production.
  • the antibodies and fragments thereof bind PD-Ll and result in an increase of one or more cytokines selected from the group consisting of IL-2, IFNy, TNF, IL-1 , IL-4, IL-5, IL-6, IL-12, IL-13, IL- 17, and GM-CSF.
  • the present invention provides methods for modulating an immune response comprising contacting T cells and antigen presenting cells with the anti-PD-Ll antibody or fragment thereof.
  • the modulation of an immune response by the anti-PD-Ll antibodies and fragments provided herein may be measured in a mixed lymphocyte (MLR) reaction.
  • the anti-PD-Ll antibodies provided herein increase the level of cytokine production from lymphocytes in an MLR.
  • the anti- PD-Ll antibodies increase the level of IL-2 production and/or IFNy production in an MLR.
  • the anti-PD-Ll antibodies increase the level of IL-2 production and IFNy production in an MLR.
  • the anti-PD-Ll antibodies enhance memory T cell responses.
  • the anti-PD-Ll antibodies enhance memory T cell responses as measured by an increase in IFNy production from memory T cells.
  • the anti-PD-Ll antibodies and fragments thereof provided herein inhibit regulatory T cell function.
  • the anti-PD-Ll antibodies and fragments thereof inhibit the suppression of effector T cells by regulatory T cells.
  • the anti-PD-Ll antibodies and fragments thereof restore the effector functions of T cells in the presence of regulatory T cells.
  • the anti-PD-Ll antibodies and fragments thereof restore the ability of effector T cells to proliferate and/or produce cytokines in the presence of regulatory T cells.
  • the present invention provides a method for inhibiting the suppressive effects of regulatory T cells in vitro or in a subject in need thereof.
  • an isolated antibody or fragment thereof that binds to PD-L1 is provided, wherein the antibody is produced by a hybridoma selected from the group consisting of the hybridomas herein termed 13C5, 5G9, 5G1 1 , 8C6, 7B4, 4D1 , 4A8, 8H4, 8H3, and 15F1.
  • the present invention also encompasses the hybridomas 13C5, 5G9, 5G1 1 , 8C6, 7B4, 4D1 , 4A8, 8H4, 8H3, and 15F1 , as well as any hybridoma producing an antibody disclosed herein.
  • the present invention also provides isolated polynucleotides encoding the antibodies and fragments thereof provided herein. Expression vectors comprising the isolated polynucleotides, and host cells comprising such expression vectors, are also encompassed in the invention.
  • the present invention provides anti-PD-Ll antibody immunoconjugates.
  • the present invention provides an antibody or fragment thereof that binds to PD-L1 and that is linked or conjugated to a therapeutic agent.
  • Therapeutic agents that may be linked or conjugated to the anti-PD-Ll antibody may include, but are not limited to, cytotoxic drugs, radioactive isotopes, immunomodulators, or antibodies.
  • the present invention provides compositions comprising one or more anti- PD-Ll antibody or fragment thereof provided herein, and a pharmaceutically acceptable carrier.
  • the present invention provides methods for modulating an immune response in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-PD-Ll antibody or fragment thereof provided herein.
  • the present invention provides methods for treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-PD-Ll antibody or fragment thereof provided herein.
  • the present invention provides a method for enhancing anti-tumor responses in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-PD-Ll antibody or fragment of the invention.
  • the present invention provides a method for reducing tumors or inhibiting the growth of tumor cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-PD-Ll antibody or fragment of the invention.
  • the present invention provides a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-PD-Ll antibody or fragment of the invention.
  • the cancer is selected from the group consisting of lymphoma, leukemia, melanoma, glioma, breast cancer, lung cancer, colon cancer, bone cancer, ovarian cancer, bladder cancer, kidney cancer, liver cancer, stomach cancer, rectal cancer, testicular cancer, salivary cancer, thyroid cancer, thymic cancer, epithelial cancer, head or neck cancer, gastric cancer, pancreatic cancer, or a combination thereof.
  • the present invention provides a method for treating an infectious disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-PD-Ll antibody or fragment of the invention.
  • the infectious disease is selected from the group consisting of candidiasis, candidemia, aspergillosis, streptococcal pneumonia, streptococcal skin and oropharyngeal conditions, gram negative sepsis, tuberculosis, mononucleosis, influenza, respiratory illness caused by Respiratory Syncytial Virus, malaria, schistosomiasis, and trypanosomiasis.
  • Figure la-d is set of graphs showing the binding of the murine hybridoma anti-PD-Ll antibodies to PD-Ll over a range of antibody concentrations as measured by ELISA. Binding of hybridoma antibodies 8H3-mIgG (m8H3), 15Fl-mIgG (ml5Fl), 5G9-mIgG (m5G9), and 4A8- mlgG (m4A8) is shown in Figure la.
  • Binding of hybridoma antibodies 5Gl l-mIgG (m5Gl l), 7B4-mIgG (m7B4), 4Dl-mIgG (m4Dl), and 8H4-mIgG (m8H4) is shown in Figure lb. Binding of hybridoma antibody 8C6-mIgG (m8C6) is shown in Figure lc. Binding of hybridoma antibody 13C5-mIgG (ml3C5) is shown in Figure Id. In each of Figures la- Id, binding of mlgGl is shown as a negative control.
  • Figure 2a-c is set of graphs showing the binding of chimeric anti-PD-Ll antibodies to PD-Ll over a range of concentrations as measured by ELISA. Binding of chimeric antibodies ch5Gl l-hIgG4 and ch5Gl l-hIgGl is shown in Figure 2a. Binding of chimeric antibodies chl3C5-hIgG4, chl3C5-hIgGl , and ch8H4-hIgG4 is shown in Figure 2b. Binding of chimeric antibody ch8C6-hIgG4 is shown in Figure 2c. In each of Figures 2a-2c, binding of hIgG4 is shown as a negative control.
  • Figure 3a-b is set of graphs showing the binding of humanized anti-PD-Ll antibodies to PD-L1 over a range of antibody concentrations as measured by ELISA. Binding of control hIgG4 and humanized antibodies hu5Gl l-hIgGl and hu5Gl l-hIgG4 is shown in Figure 3a. Binding of control hIgG4 and humanized antibodies hul3C5-hIgGl and hul3C5-hIgG4 is shown in Figure 3b.
  • Figure 4a-c is a set of graphs showing the blockage of the PD-l/PD-Ll interaction by hybridoma anti-PD-Ll antibodies over a range of antibody concentrations as measured by ELISA. Blockage of PD-l/PD-Ll binding by hybridoma antibodies 13C5-mIgG (ml3C5), 8C6-mIgG (m8C6), 5G9-mIgG (m5G9), and 4A8-mIgG (m4A8) as compared to control mlgGl is shown in Figure 4a.
  • Blockage of PD-l/PD-Ll binding by hybridoma antibodies 5Gl l-mIgG (m5Gl l), 7B4-mIgG (m7B4), 4Dl-mIgG (m4Dl), and 8H4-mIgG (m8H4) as compared to control mlgGl is shown in Figure 4b.
  • Blockage of PD-l/PD-Ll binding by hybridoma antibodies 8H3-mIgG (m8H3) and 15Fl-mIgG (ml5Fl) as compared to control mlgGl is shown in Figure 4c.
  • Figure 5a-c is a set of graphs showing the blockage of the PD-l/PD-Ll interaction by chimeric anti-PD-Ll antibodies over a range of antibody concentrations as measured by ELISA.
  • Blockage of PD-l/PD-Ll binding by chimeric antibodies ch5Gl l hIgG4 and ch5Gl l hlgGl as compared to control hIgG4 is shown in Figure 5a.
  • Blockage of PD-l/PD-Ll binding by chimeric antibody ch8C6-hIgG4 as compared to control hIgG4 is shown in Figure 5b.
  • Blockage of PD-l/PD-Ll binding by chimeric antibodies ch8H4-hIgG4, chl3C5-hIgGl, and chl3C5-hIgG4 as compared to control hIgG4 is shown in Figure 5c.
  • Figure 6a-b is a set of graphs showing the blockage of the PD-l/PD-Ll interaction by humanized anti-PD-Ll antibodies over a range of antibody concentrations as measured by ELISA.
  • Blockage of PD-l/PD-Ll binding by control hIgG4 and humanized antibodies 5G11- hlgGl and 5Gl l-hIgG4 is shown in Figure 6a.
  • Blockage of PD-l/PD-Ll binding by control hIgG4 and humanized antibodies 13C5-hIgGl and 13C5-hIgG4 is shown in Figure 6b.
  • Figure 7a and 7b show the binding of the hybridoma anti-PD-Ll antibodies to PD-L1 over a range of antibody concentrations as measured by FACS. Binding (as measured by the mean fluorescence intensity) of hybridoma antibodies 4A8, 15F1, 4D1 , 13C5, 8H4, and 8H3 as compared to control antibody mlgGl is shown in Figure 7a. Binding (as measured by the mean fluorescence intensity) of hybridoma antibodies 5G11, 8C6, 5G9, or 7B4 as compared to control antibody mlgGl is shown in Figure 7b.
  • Figure 8 shows the binding of the chimeric anti-PD-Ll antibodies to PD-L1 over a range of antibody concentrations as measured by FACS. Binding of control antibody hIgG4, and chimeric antibodies chl3C5-hIgGl, ch5Gl 1-hIgGl , and ch5Gl l-hIgG4 are shown.
  • Figure 9 shows the binding of humanized anti-PD-Ll antibodies to PD-L1 over a range of antibody concentrations as measured by FACS. Binding of control antibody hIgG4 and humanized antibodies hul3C5-hIgGl , hul3C5-hIgG4, hu5Gl 1-hIgGl, and hu5Gl l-hIgG4 are shown.
  • Figure 10a and 10b show the blockage of the PD-1/PD-L1 interaction by hybridoma anti-PD-Ll antibodies over a range of antibody concentrations as measured by FACS.
  • Blockage of PD-1/PD-L1 binding by control antibody mlgGl and hybridoma antibodies m4Dl , m5Gl l , ml3C5, m7B4, and m8H4 is shown in Figure 10a.
  • Blockage of PD-1/PD-L1 binding by control antibody mlgGl and hybridoma antibodies m4A8, m5G9, m8C6, m8H3, and ml5Fl is shown in Figure 10b.
  • Figure 11 shows the blockage of the PD-1/PD-L1 interaction over a range of concentrations of control antibody hIgG4 or chimeric anti-PD-Ll antibodies ch8C6-hIgG4, ch5Gl l-hIgGl, ch5Gl l-hIgG4, chl3C5-hIgGl , chl3C5-hIgG4, or ch8H4-hIgG4, as measured by FACS.
  • Figure 12 shows the blockage of the PD-1/PD-L1 interaction over a range of concentrations of control antibody hIgG4 or humanized antibodies hu 13C5-hIgGl , hul3C5- hIgG4, hu5Gl 1-hIgGl , or hu5Gl l-hIgG4, as measured by FACS.
  • Figure 13a is a graph showing IL-2 (pg/mL) production in an MLR in response to different concentrations of hybridoma anti-PD-Ll antibodies.
  • Figure 13b is a graph showing IFNy (pg/mL) production in an MLR in response to different concentrations of hybridoma anti- PD-Ll antibodies.
  • the antibodies tested were, from left to right, control mlgGl, m8C6, m4Dl, m5Gl 1, m7B4, m8H4, m5G9, ml3C5, m8H3, and ml5Fl .
  • T cell only and/or DC only wells were also included as negative controls.
  • Figure 14a is a graph showing IL-2 (pg/mL) production in an MLR in response to different concentrations of chimeric anti-PD-Ll antibodies.
  • Figure 14b is a graph showing IFNy (pg/mL) production in an MLR in response to different concentrations of chimeric anti-PD-Ll antibodies.
  • each antibody tested was tested at 20 ⁇ g/mL, 2 ⁇ g/mL, 0.2 ⁇ g/mL, 0.02 ⁇ g/mL, and 0.002 ⁇ g/mL.
  • Figure 15a is a graph showing IL-2 (pg/mL) production in an MLR in response to different concentrations of humanized anti-PD-Ll antibodies.
  • Figure 15b is a graph showing IFNy (pg/mL) production in an MLR in response to different concentrations of humanized anti- PD-Ll antibodies.
  • the antibodies tested were, from left to right, control hIgG4, hul3C5-hIgGl , hul3C5-hIgG4, hu5Gl 1-hIgGl , and hu5Gl l-hIgG4.
  • each antibody was tested at 20 ⁇ g/mL, 2 ⁇ g/mL, 0.2 ⁇ g/mL, 0.02 ⁇ g/mL, and 0.002 ⁇ g/mL.
  • Figure 16 shows the effects of chimeric (ch) or humanized (hu) anti-PD-Ll antibodies on Treg-mediated inhibition of IFNy production (pg/mL), in an allogeneic MLR with CD4+ CD25+ Treg cells, CD4+CD25- T cells, and dendritic cells.
  • the antibodies tested were, from left to right, control hIgG4, chl3C5-hIgGl , chl3C5-hIgG4, hul3C5-hIgGl, hul3C5-hIgG4, ch5Gl l- hlgGl, ch5Gl l-hIgG4, hu5Gl 1-hIgGl, and hu5Gl l-hIgG4.
  • Figure 17 shows IFN- ⁇ production (pg/mL) from T cells in response to costimulation with autologous DCs and anti-CD3 antibody, in the presence of humanized anti-PD-Ll antibody (hul3C5-hIgGl, hul3C5-hIgG4, hu5Gl 1-hIgGl, or hu5Gl l-hIgG4), isotype control (hIgG4) antibody, or no antibody.
  • humanized anti-PD-Ll antibody hul3C5-hIgGl, hul3C5-hIgG4, hu5Gl 1-hIgGl, or hu5Gl l-hIgG4
  • isotype control (hIgG4) antibody or no antibody.
  • Figures 18a and 18b show the effect of humanized anti-PD-Ll antibodies on memory T cell responses recalled by tetanus toxin, as measured by IFN- ⁇ production (pg/mL).
  • Negative control hIgG4 or humanized antibody hul3C5-hIgGl , hul3C5-hIgG4, hu5Gl 1-hIgGl, or hu5Gl l-hIgG4 were tested at the following concentrations: 20 ⁇ g/mL, 2 ⁇ g/mL, 0.2 ⁇ g/mL, 0.02 ⁇ g/mL, and 0.002 ⁇ g/mL.
  • PD1/PDL1 interactions inhibit T cell receptor signaling by recruiting the SHP1 and SHP2 phosphatases, which interfere with TCR signaling (Chemnitz et al. (2004) J. Immunol. 17:945- 954).
  • PD-Ll can not only promote tumor progression through inhibition of PD1 -expressing immune effectors, but also modulate cell-mediated immunity in some infectious diseases (Mueller et al. (2010) J. Clin. Invest. 120:2508-2515).
  • allogeneic effector T cell responses are susceptible to PD-1 pathway modulation in graft rejection (Lee et al. (2003) J. Immunol. 171 :6929-6935).
  • the interaction of PD-1 with PD-Ll exerts a vital and diverse range of immunoregulatory roles in T cell activation, tolerance, and immune-mediated tissue damage.
  • the interaction can be reversed by blocking the local binding of PD-1 with PD-Ll (Iwai et al. (2002) Proc. Nat'l. Acad Sci. USA 99: 12293-7; Brown et al. (2003) J. Immunol. 170: 1257-66).
  • PD-1 has been found to have a correlation with cancer growth and development due to its role in protecting tumor cells from efficient immune destruction. Its ligand, PD-Ll , has been revealed to have significant expression on a number of mouse and human tumors, which is postulated to mediate immune evasion (Iwai, Y. et al., Proc. Natl. Acad. Sci. USA.99: 12293- 12297 (2002); Strome S. E. et al, Cancer Res., 63:6501-6505 (2003); Dong et al. (2002) Nat. Med. 8:787-9).
  • PD-1 on tumor infiltrating lymphocytes
  • PD-Ll on tumor cells
  • Such tissues include cancers of the lung, liver, ovary, cervix, skin, colon, glioma, bladder, breast, kidney, esophagus, stomach, oral squamous cell, urothelial cell, and pancreas as well as tumors of the head and neck (Brown J. A.et al., J. Immunol. 170: 1257-1266 (2003); Dong H. et al, Nat.Med. 8: 793-800 (2002); Wintterle et al, Cancer Res.
  • PD-1 blockade using a fully human anti-PD-1 antibody augmented the absolute numbers of tumor-specific CD8+ T cells (CTLs) in ex vivo stimulation assays using vaccine antigens and cells from vaccinated individuals.
  • CTLs tumor-specific CD8+ T cells
  • antibody blockade of PD-L1 resulted in enhanced cytolytic activity of tumor-associated antigen-specific cytotoxic T cells and increased cytokine production by tumor specific TH cells (Blank C. et al., Int. J. Cancer 1 19: 317-327 (2006)).
  • the same authors showed that PD-L1 blockade augments tumor-specific T cell responses in vitro when used in combination with anti-CTLA-4 blockade.
  • Anti-PD-Ll antibodies may also be useful in chronic viral infection.
  • Memory CD8+ T cells generated after an acute viral infection are highly functional and constitute an important component of protective immunity.
  • chronic infections are often characterized by varying degrees of functional impairment (exhaustion) of virus-specific T-cell responses, and this defect is a principal reason for the inability of the host to eliminate the persisting pathogen.
  • functional effector T cells are initially generated during the early stages of infection, they gradually lose function during the course of a chronic infection. Barber et al.
  • mice infected with a laboratory strain of LCMV developed chronic infection resulting in high levels of virus in the blood and other tissues. These mice initially developed a robust T cell response, but eventually succumbed to the infection upon T cell exhaustion. The authors found that the decline in number and function of the effector T cells in chronically infected mice could be reversed by injecting an antibody that blocked the interaction between PD-1 and PD-Ll.
  • the present invention provides antibodies or antigen binding fragments thereof that bind to programmed death ligand 1 (PD-Ll).
  • the antibodies or fragments thereof bind to human PD-Ll .
  • the antibodies or fragments thereof bind to human and to cynomolgous PD-Ll .
  • the antibodies or fragments thereof block the interaction of PD-Ll with its receptor PD- 1 on T cells.
  • the present invention provides methods of making and using the anti-PD-Ll antibodies or fragments thereof, and compositions comprising anti-PD-Ll antibodies or fragments thereof, including pharmaceutical compositions.
  • the term "antibody” refers to a binding protein having at least one antigen binding domain.
  • the antibodies and fragments thereof of the present invention may be whole antibodies or any fragment thereof.
  • the antibodies and fragments of the invention include monoclonal antibodies or fragments thereof and antibody variants or fragments thereof, as well as immunoconjugates.
  • Examples of antibody fragments include Fab fragments, Fab' fragments, F(ab)' fragments, Fv fragments, isolated CDR regions, single chain Fv molecules (scFv), and other antibody fragments known in the art.
  • Antibodies and fragments thereof may also include recombinant polypeptides, fusion proteins, and bi-specific antibodies.
  • the anti-PD-Ll antibodies and fragments thereof disclosed herein may be of an IgGl , IgG2, IgG3, or IgG4 isotype.
  • the term "isotype" refers to the antibody class encoded by the heavy chain constant region genes.
  • the anti-PD-Ll antibodies and fragments thereof disclosed herein are of an IgGl or an IgG4 isotype.
  • the PD-Ll antibodies and fragments thereof of the present invention may be derived from any species including, but not limited to, mouse, rat, rabbit, primate, llama, and human.
  • the PD-L1 antibodies and fragments thereof may be chimeric, humanized, or fully human antibodies.
  • the anti-PD-Ll antibodies are antibodies produced by a hybridoma cell line derived from a mouse.
  • the anti-PD-Ll antibodies are murine antibodies.
  • the anti-PD-Ll antibodies are chimeric antibodies.
  • the chimeric antibodies are mouse-human chimeric antibodies.
  • the antibodies are humanized antibodies.
  • the antibodies are derived from murine antibodies and are humanized.
  • a “chimeric antibody” is an antibody having at least a portion of the heavy chain variable region and at least a portion of the light chain variable region derived from one species; and at least a portion of a constant region derived from another species.
  • a chimeric antibody may comprise murine variable regions and a human constant region.
  • a “humanized antibody” is an antibody containing complementarity determining regions (CDRs) that are derived from a non-human antibody; and framework regions as well as constant regions that are derived from a human antibody.
  • CDRs complementarity determining regions
  • the anti-PD-Ll antibodies provided herein may comprise CDRs derived from one or more murine antibodies and human framework and constant regions.
  • the humanized antibody provided herein binds to the same epitope on PD-L1 as the murine antibody from which the antibody's CDRs are derived.
  • Exemplary humanized antibodies are provided herein.
  • framework sequences suitable for use in the present invention include those framework sequences that are structurally similar to the framework sequences provided herein. Further modifications in the framework regions may be made to improve the properties of the antibodies provided herein. Such further framework modifications may include chemical modifications; point mutations to reduce immunogenicity or remove T cell epitopes; or back mutation to the residue in the original germline sequence. In some embodiments, such modifications include those corresponding to the mutations exemplified herein, including backmutations to the germline sequence.
  • one or more amino acids in the human framework regions of the VH and/or VL of the humanized antibodies provided herein are back mutated to the corresponding amino acid in the parent murine antibody.
  • VH and VL of humanized 5G1 1 and humanized 13C5 several sites of framework amino acid of the aforementioned template human antibody were back mutated to the corresponding amino acid sequences in mouse 5G1 1 and 13C5 antibodies.
  • the amino acid at positions 53 and/or 60 and/or 67 of the light chain variable region is back mutated to the corresponding amino acid found at that position in the mouse 5G1 1 or 13C5 light chain variable region.
  • the amino acid at positions 24 and/or 28 and/or 30 and/or 49 and/or 73 and/or 83 and/or 94 of the heavy chain variable region is back mutated to the corresponding amino acid found at that position in the mouse 5G1 1 or 13C5 heavy chain variable region.
  • the humanized 5G1 1 antibody comprises a light chain variable region wherein the amino acid at position 60 is mutated from Ser (S) to Asp (D) and the amino acid at position 67 is mutated from Ser (S) to Tyr (Y); and a heavy chain variable region wherein the amino acid at position 24 is mutated from Phe (F) to Val (V), the amino acid at position 49 is mutated from Ala (A) to Gly (G), the amino acid at position 73 is mutated from Thr (T) to Asn (N), and the amino acid at position 83 is mutated from Thr (T) to Asn (N).
  • the humanized 13C5 antibody comprises a light chain variable region wherein the amino acid at position 53 is mutated from Tyr (Y) to Lys (K); and a heavy chain variable region wherein the amino acid at position 28 is mutated from Thr (T) to He (I), the amino acid at position 30 is mutated from Ser (S) to Arg (R), the amino acid at position 49 is mutated from Ser (S) to Ala (A), and the amino acid at position 94 is mutated from Tyr (Y) to Asp (D). Additional or alternate back mutations may be made in the framework regions of the humanized antibodies provided herein in order to improve the properties of the antibodies.
  • the present invention also encompasses humanized antibodies that bind to PD-L1 and comprise framework modifications corresponding to the exemplary modifications described herein with respect to any suitable framework sequence, as well as other framework modifications that otherwise improve the properties of the antibodies.
  • the antibodies and antigen-binding fragments thereof disclosed herein are specific for PD-Ll . In one embodiment, the antibodies and fragments thereof are specific for human PD-Ll . In one embodiment, the antibodies and fragments provided herein bind to human or primate PD- Ll but not to PD-Ll from any other mammal. In a further embodiment, the antibodies and fragments thereof do not bind to mouse PD-Ll .
  • human PD-Ll refers to human PD-Ll and variants or isoforms of human PD-Ll .
  • specific for is meant that the antibodies and fragments thereof bind PD-Ll with greater affinity than any other target.
  • EC50 refers to the effective concentration, 50% maximal response of the antibody.
  • IC50 refers to the inhibitory concentration, 50% maximal response of the antibody. Both EC50 and IC50 may be measured by ELISA or FACS analysis, or any other method known in the art.
  • the anti-PDl antibodies and fragments or variants thereof have a binding affinity (KD) for PD-Ll in the range of about 0.001 nM to about 100 nM, about 0.002 nM to about 50 nM, about 0.005 nM to about 5 nM, about 0.01 nM to about 1 nM, or about 0.05 nM to about 0.1 nM.
  • KD binding affinity
  • the antibodies and fragments thereof have a binding affinity (KD) for PD-Ll of about 50 nM or less, about 25 nM or less, about 20 nM or less, about 15 nM or less, about 10 nM or less, about 8 nM or less, about 6 nM or less, about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2 nM or less, about 1 nM or less, about 0.9 nM or less, about 0.8 nM or less, about 0.7 nM or less, about 0.6 nM or less, about 0.5 nM or less, about 0.4 nM or less, about 0.3 nM or less, about 0.2 nM or less, about 0.1 nM or less, about 0.09 nM or less, about 0.08 nM or less, about 0.07 nM or less, about 0.06 nM or less, about 0.05 nM or less, about 0.04 nM or
  • the antibodies and fragments thereof have a binding affinity (KD) for PD-Ll of about 10 nM, about 9 nM, about 8 nM, about 7 nM, about 6 nM, about 5 nM, about 4 nM, about 3 nM, about 2 nM, about 1 nM, about 0.9 nM, about 0.8 nM, about 0.7 nM, about 0.6 nM, about 0.5 nM, about 0.4 nM, about 0.3 nM, about 0.2 nM, about 0.1 nM, about 0.09 nM, about 0.08 nM, about 0.07 nM, about 0.06 nM, about 0.05 nM, about 0.04 nM, about 0.03 nM, about 0.02 nM, about 0.01 nM, about 0.009 nM, about 0.008 nM, about 0.007 nM, about 0.006 nM, about 0.005 nM, about 0.00
  • the antibodies and fragments provided herein comprise a light chain and a heavy chain, each of which comprises three CDR regions.
  • Exemplary heavy chain CDR sequences (HCDR1, HCDR2, and HCDR3) for PD-L1 antibodies of the invention are provided below in Table 1.
  • Exemplary light chain CDR sequences (LCDRl, LCDR2, and LCDR3) for PD-L1 antibodies of the invention are provided below in Table 2.
  • Exemplary variable regions and full length heavy and light chain sequences for PD-L1 antibodies of the invention are provided below in Table 3.
  • the invention provides anti-PD-Ll antibodies that comprise the chain CDRs and heavy chain CDRs of antibodies 13C5, 5G9, 5G1 1 , 8C6, 7B4, 4D1 , 4A8, 8H4, 8H3, and/or 15F1.
  • the person of skill in the art will understand that the heavy and light chain CDRs of the antibodies provided herein may be independently selected, or mixed and matched, to form an antibody or binding fragment thereof comprising any heavy chain CDRl , CDR2, and CDR3; and any light chain CDRl , CDR2, and CDR3 from the antibodies provided herein.
  • the invention provides anti-PD-Ll antibodies that comprise a heavy chain CDRl comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 81 , 87, 93, 99, 105, 1 1 1 , 1 17, 123, 129, and 135; a heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 82, 88, 94, 100, 106, 1 12, 1 18, 124, 130, and 136; a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 83, 89, 95, 101 , 107, 1 13, 1 19, 125, 131 , and 137; a light chain CDRl comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 84, 90, 96, 102, 108, 1 14, 120, 126, 132, and 138; a light chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ
  • the present invention provides anti-PD-Ll antibodies comprising heavy and light chain CDR regions comprising amino acid sequences having at least 75%, at least 80%, at least at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology to the corresponding light or heavy chain CDR1 , CDR2, or CDR3 provided herein.
  • the present invention provides anti-PD-Ll antibodies comprising heavy and light chain CDR regions comprising amino acid sequences having 1 , 2, 3, 4, 5, or 6 amino acid substitutions, deletions, or insertions relative to the corresponding light or heavy chain CDR1 , CDR2, or CDR3 provided herein.
  • the invention provides anti-PD-Ll antibodies that comprise a variable heavy chain of an antibody selected from the group consisting of 13C5, 5G9, 5G1 1 , 8C6, 7B4, 4D1 , 4A8, 8H4, 8H3, and/or 15F1 and a variable light chain of an antibody selected from the group consisting of 13C5, 5G9, 5G1 1 , 8C6, 7B4, 4D1 , 4A8, 8H4, 8H3, and/or 15F1.
  • the antibodies and fragments provided herein comprise a heavy chain variable region comprising an amino acid sequence that is at least 75%, at least 80%, at least at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology to a heavy chain variable region selected from the group consisting of SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.
  • the antibodies and fragments provided herein comprise a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, or a variant thereof, wherein the variant comprises 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions or deletions, or a combination thereof.
  • the amino acid substitutions are conservative substitutions.
  • the antibodies and fragments provided herein comprise a light chain variable region comprising an amino acid sequence that is at least 75%, at least 80%, at least at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology to a light chain variable region selected from the group consisting of SEQ ID NOs: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, or 48.
  • the antibodies and fragments provided herein comprise a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, or a variant thereof, wherein the variant comprises 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acid substitutions, insertions, or deletions, or a combination thereof.
  • the amino acid substitutions are conservative substitutions.
  • the anti-PD-Ll antibodies disclosed herein having one or more amino acid substitution, insertion, deletion, or combination thereof in the CDR or variable light or heavy chain region retain the biological activity of the corresponding anti-PD-Ll antibody that does not have an amino acid substitution, insertion, or deletion.
  • the variant anti-PD-Ll antibodies provided herein retain binding to PD-Ll .
  • Percent homology refers to the number of identical amino acid sequences shared by two reference sequences, divided by the total number of amino acid positions, multiplied by 100.
  • the anti-PD-Ll antibodies provided herein comprise conservative amino acid substitutions.
  • a conservative amino acid substitution is a substitution of one amino acid with another amino acid that has a similar structural or chemical properties, such as, for example, a similar side chain.
  • Exemplary conservative substitutions are described in the art, for example, in Watson et ah, Molecular Biology of the Gene, The Bengamin/Cummings Publication Company, 4 th Ed. (1987).
  • variable light and variable heavy chains may be independently selected, or mixed and matched, from the antibodies provided herein.
  • the present invention provides anti-PD-Ll antibodies comprising a heavy chain variable region having at least 80% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46; and a light chain variable region having at least 80% homology to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
  • the present invention provides antibodies that bind to the same epitope as any one of the exemplary antibodies disclosed herein.
  • the present invention provides antibodies that compete for binding to PD-Ll with the exemplary antibodies provided herein.
  • the anti-PD-Ll antibodies and fragments thereof provided herein may further comprise Fc region modifications to alter effector functions.
  • Fc modifications may be amino acid insertions, deletions, or substitutions, or may be chemical modifications.
  • Fc region modifications may be made to increase or decrease complement binding, to increase or decrease antibody-dependent cellular cytoxicity, or to increase or decrease the half life of the antibody.
  • Some Fc modifications increase or decrease the affinity of the antibody for an Fey receptor such as FcyRI, FcyRII, FcyRIII, or FcRn.
  • Fc modifications have been described in the art, for example, in Shields et al, J Biol. Chem 276; 6591 (2001); Tai et al.
  • Fc region glycosylation patters are altered.
  • the Fc region is modified by pegylation (e.g., by reacting the antibody or fragment thereof with polyethylene glycol (PEG).
  • the antibodies or fragments thereof provided herein are immunoconjugates comprising an anti-PD-Ll antibody or fragment thereof and further comprising an agent selected from the group including an additional therapeutic agent, a cytotoxic agent, an immunoadhesion molecule, and an imaging agent.
  • the imaging agent is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and biotin.
  • the imaging agent is a radiolabel selected from the group consisting of: 3 ⁇ 4 14 C 35 S, 62 Cu, 64 Cu, 89 Zr, 90 Y, "Tc, m In, 125 I, 131 I, 177 Lu, 166 Ho, and 153 Sm.
  • the therapeutic agent or cytotoxic agent is selected from the group including a chemotherapeutic agent, an immunosuppressive agent, an immuno-stimulatory agent, an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an antimitotic agent, an anthracycline, a toxin, and an apoptotic agent.
  • the binding protein is conjugated directly to the agent. In other embodiments, the binding protein is conjugated to the agent via a linker.
  • Suitable linkers include, but are not limited to, amino acid and polypeptide linkers disclosed herein. Linkers may be cleavable or non-cleavable.
  • the present invention provides bispecific or multispecific antibodies specific for PD-Ll and at least one other antigen or epitope.
  • the anti-PD-Ll antibodies and fragments thereof provided herein may be tested for binding to PD-Ll using the binding assays provided herein, or any other binding assay known in the art.
  • the present invention provides methods for treating a subject for a disease or condition responsive to enhancing, stimulating, or eliciting an immune response.
  • treatment or “treating” refers to both therapeutic treatment and prophylactic or preventive measures.
  • Subjects in need of treatment include those subjects that already have the disease or condition, as well as those that may develop the disease or condition and in whom the object is to prevent, delay, or diminish the disease or condition.
  • subject denotes a mammal, such as a rodent, a feline, a canine, and a primate.
  • a subject according to the invention is a human.
  • terapéuticaally effective amount refers to the amount of a compound or composition that is necessary to provide a therapeutic and/or preventative benefit to the subject.
  • the antibodies and antigen binding fragments thereof are useful in the treatment of solid or non-solid tumors.
  • the present invention provides methods for treatment of cancer.
  • Cancer refers to the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • cancer examples include but are not limited to carcinoma, lymphoma, blastoma, sarcoma (including liposarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, leiomyosarcoma, chordoma, lymphangiosarcoma, lymphangioendotheliosarcoma, rhabdomyosarcoma, fibrosarcoma, myxosarcoma, chondrosarcoma), neuroendocrine tumors, mesothelioma, synovioma, schwanoma, meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies.
  • sarcoma including liposarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, leiomyosarcoma, chordoma, lymphangiosarcoma, lymph
  • squamous cell cancer e.g. epithelial squamous cell cancer
  • Hodgkin's lymphoma e.g. epithelial squamous cell cancer
  • non-Hodgkin's lymphomas Bovine's lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mycosis fungoides, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, hairy cell leukemia and lymphoplasmacytic leukemia
  • tumors of lymphocyte precursor cells including B-cell acute lymphoblastic leukemia/lymphoma, and T-cell acute lymphoblastic leukemia/lymphoma, thymoma, tumors of the mature T and NK cells, including peripheral T-cell leukemias, adult T-cell leukemia/T-cell lymphomas and large granular lymphocytic leukemia
  • the antibodies and fragments thereof provided herein are useful in the treatment of diseases caused by infectious agents.
  • infectious agents include, but are not limited to, bacterial, mycological, parasitic, and viral agents.
  • infectious agents include the following: staphylococcus, methicillin-resistant staphylococcus aureus, Escherichia coli, streptococcaceae, neisseriaaceae, cocci, enterobacteriaceae, enterococcus, vancomycin- resistant enterococcus, cryptococcus, histoplasmosis, aspergillus, pseudomonadaceae, vibrionaceae, Campylobacter, pasteurellaceae, bordetella, francisella, brucella, legionellaceae, bacteroidaceae, gram-negativebacilli, Clostridium, corynebacterium, propionibacterium, gram- positive bacilli, anthrax, actinom
  • infectious diseases include but are not limited to candidiasis, candidemia, aspergillosis, streptococcal pneumonia, streptococcal skin and oropharyngeal conditions, gram negative sepsis, tuberculosis, mononucleosis, influenza, respiratory illness caused by Respiratory Syncytial Virus, malaria, schistosomiasis, and trypanosomiasis.
  • the antibodies and fragments thereof provided herein are useful in the treatment of diseases mediated by T-helper type 2 (Th2) T cells, such as, for example, asthma, allergy, or graft versus host disease.
  • Th2 T-helper type 2
  • the antibodies and fragments thereof provided herein are useful in for the stimulation of an immune response in a subject in need thereof.
  • the anti-PD-Ll antibodies and fragments thereof may be administered in conjunction with an antigen of interest for the purpose of eliciting an immune response to said antigen.
  • An antigen of interest may be an antigen associated with a pathogen such as a virus or bacterium.
  • the present invention provides a vaccine comprising an anti-PD-Ll antibody and an antigen, wherein the vaccine elicits an antigen-specific immune response.
  • the anti-PD-Ll antibodies provided herein modulate regulatory T cell function.
  • CD4+ CD25+ regulatory T cells are lymphocytes that suppress or reduce the effects of effector T cell functions.
  • the terms "regulatory T cell” and “Treg” are used interchangeably herein.
  • the anti-PD-Ll antibodies provided herein prevent or reverse the inhibitory effects of regulatory T cells on effector T cell cytokine production.
  • the anti-PD-Ll antibodies provided herein restore the capacity for IFNy production to effector T cells in contact with regulatory T cells.
  • the antibodies and fragments thereof disclosed herein may be administered to the subject by at least one route selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intratympanic, intrauterine, intravesical, intravitreal, bolus, subconjunctival, vaginal, rectal, buccal, sublingual, intranasal, intratumoral, and transdermal.
  • parenteral subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraa
  • the antibodies and fragments thereof disclosed herein may be administered to a subject in need thereof in combination with one or more additional therapeutic agent.
  • the antibodies and fragments thereof may be administered to a subject before, during, and/or after administration to the subject of the additional therapeutic agent.
  • the additional therapeutic agent is a chemotherapeutic agent, radiotherapeutic agent, cytokine, antibody or fragment thereof, or any other additional therapeutic that is indicated for the disease to be treated.
  • the anti-PD-Ll antibody and the additional therapeutic agent exhibit therapeutic synergy when administered together, whether concurrently or sequentially.
  • the anti-PD-Ll antibody and the additional therapeutic agent are administered in separate formulations.
  • the anti-PD-Ll antibody and the additional therapeutic agent are administered in the same formulation.
  • the anti-PD-Ll antibodies and fragments provided herein enhance the immune modulating effect of the one or more additional therapeutic agent.
  • the one or more additional therapeutic agent enhances the effect of the anti-PD-Ll antibody or fragment thereof.
  • the present invention provides isolated antibodies and antigen binding fragments thereof, and nucleic acids encoding such antibodies and fragments, as well as compositions comprising such isolated antibodies, fragments, and nucleic acids.
  • isolated refers to a compound of interest (e.g., an antibody or nucleic acid) that has been separated from its natural environment.
  • present invention further provides pharmaceutical compositions comprising the isolated antibodies or fragments thereof, or nucleic acids encoding such antibodies or fragments, and further comprising one or more pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers include, for example, excipients, diluents, encapsulating materials, fillers, buffers, or other agents.
  • mice After transient expression in freestyle 293 cells, hPD-Ll-HisTag was purified with NTA column (GE healthcare), hPD-Ll-mFc and hPD-Ll-hFc were purified with Protein G column (GE healthcare).
  • hPD-Ll-HisTag was purified with NTA column (GE healthcare)
  • hPD-Ll-mFc was purified with Protein G column (GE healthcare).
  • Protein G column GE healthcare
  • BALB/cJ mice were immunized subcutaneously every 2 weeks for 6 weeks with recombinant hPD-Ll-HisTag protein (10( ⁇ g/mouse) or hPD-Ll-mFc emulsified with an equal volume of Freund's complete/incomplete adjuvant. Three days before fusion, mice were boosted by intravenous injection of the antigen without adjuvant.
  • Spleen cells (1 x 10 ) from immunized mouse were fused with SP2/0 myeloma cells (1.5x l0 7 ) with PEG Hybri-Max (Sigma Inc., CAT#:7181). After fusion, the cells were distributed into 96-well plates at 0.1 ml per well and incubated at 37°C, 5% C0 2 incubator. On day 1, cells were fed by adding an additional 0.1 ml per well with media containing serum and HAT plus 2 x methotrexate. On day 3 and day 7, 0.1 ml of media from each well was replaced with 0.1 ml of fresh HT media. The screening typically occurred between days 9-14, and culture supernatant was tested for antibody reacting with hPD- Ll-hFc by ELISA.
  • the hybridoma cells were cultured in Dulbecco's Modified Eagle's medium (GIBCO; Invitrogen Corporation, Carlsbad, Calif.) containing 10% fetal calf serum, 1% penicillin/streptomycin, 2% L-glutamine, and 1% adjusted NaHC0 3 solution.
  • the selected hybridoma cells were then adapted in serum free culture medium and the antibody was purified from the supernatant using Protein- G column (GE healthcare). After washing with PBS, bound antibodies were eluted using 0.1 M Glycine pH3.0, followed by pH neutralization using 2.0 M Tris. Ultra-15 centrifugal concentrators (Amicon) were used for buffer exchanging and antibody concentrating.
  • R easy Mini Kit (Qiagen, CAT#:74104) was used as the template to synthesize first-strand cDNA with Superscript® II Reverse Transcriptase (Life Technology, CAT#: 18064-14) according to the manufacturer's instructions.
  • the cDNA product was then subjected to PCR in a 50 ⁇ volume reaction mixture using degenerate mouse IgG primers (Kettleborough CA, et al, European Journal of Immunology 23: 206-211 (1993), Strebe N, et al, Antibody Engineering 1 :3-14 (2010)).
  • the reaction was carried out in a S1000TM Thermal Cycler (Bio-Rad, CAT#: 184- 2000) with 30 cycles of: 94° C, 1.5 minutes for denaturation; 50° C, 1 minutes for annealing; and 72° C, 1 minute for synthesis. At the end of the 30th cycle, the reaction mixture was incubated another 7 minutes at 72° C for extension.
  • S1000TM Thermal Cycler Bio-Rad, CAT#: 184- 2000
  • PCR mixture was subjected to electrophoresis in a 1% agarose/Tris-Borate gel containing 0.5 ⁇ g/ml ethidium bromide.
  • DNA fragments having the expected sizes (approximately 450 bp for the heavy chain and the light chain) were excised from the gel and purified.
  • 3 ⁇ of purified PCR product were cloned into the pMD-18T vector (Takara, CAT#:D101A) and transformed into One Shot® TOP 10 chemically competent E. coli (Invitrogen, CAT#:C4040-03). Clones were screened by colony PCR using universal M13 forward and reverse primers, and 10 positive clones from each reaction were chosen for DNA sequencing in both directions using M13 forward and M13 reverse primers.
  • mice 68 were constructed by linking the PCR-cloned cDNAs of mouse VL regions to human kappa chain constant region, respectively.
  • 8C6, 8H4, 5G1 1 and 13C5 chimeric heavy chains (SEQ ID NOs: 50 (8C6-IgG4), 54 (8H4-IgG4), 58 (5Gl l-IgGl), 60 (5Gl l-IgG4), 64 (13C5-IgGl), and 66 (13C5-IgG4)) were constructed by linking the PCR-cloned cDNAs of mouse VH regions to human IgGl and IgG4 constant regions.
  • the 5'ends of the mouse cDNA sequences were modified using PCR primers designed to add a leader sequence to both light chain and heavy chain.
  • Freestyle 293 cells (200 mL at 10 6 /mL) were transfected with 100 ⁇ g of each of the chimeric heavy and light chain expression plasmids and cultured for 6 days.
  • the chimeric antibody in the supernatant was then purified with Protein-G column (GE healthcare). Binding of the chimeric antibody with PD-Ll was measured by ELISA and Biacore, and was shown to bind to PD-Ll with comparable affinity to that of the murine parent antibody.
  • Antibody humanization design 200 mL at 10 6 /mL
  • 5G11 and 13C5 antibodies were humanized using CDR grafting approach (see, for example, U.S. Pat. No.5,225,539).
  • the light chain and heavy chain variable chain sequences of the murine antibody 5G11 and 13C5 were compared to those available in the Research Collaboratory for Structural Bioinformatics (RCSB) protein databank (http://www.ncbi.nlm.nih.gov/igblast/igblast.cgi).
  • the model of 5G1 1 and 13C5 were generated respectively based on the VH and VL structure with the highest sequence homology.
  • the template human antibodies to be grafted with the complementary determining regions (CDRs) in the VH and VL of mouse 5G1 1 and 13C5 antibody were selected from human antibody germlines having high sequence homology with mouse 5G1 1 and 13C5 antibody by searching the international immunogenetics information system website (http://www.imgt.org/3Dstructure-DB/cgi/DomainGapAlign.cgi).
  • CDRs complementary determining regions
  • CDR amino acid sequences of the aforementioned template human antibodies were substituted by the CDRs of hybridoma (mouse) 5G1 1 (SEQ ID NOs 93-98) and 13C5 (SEQ ID NOs 81-86) antibodies.
  • the frameworks of the above-mentioned template human antibody VH and VL were grafted with the necessary amino acid sequences from VH and VL of mouse 5G1 1 and 13C5 antibody to give a functional humanized antibody.
  • VH and VL of 5G11 and 13C5 several sites of framework amino acid of the aforementioned template human antibody were backmutated to the corresponding amino acid sequences in mouse 5G1 1 and 13C5 antibody.
  • the amino acid at position 60 is mutated from Ser (S) to Asp (D), and the amino acid at position 67 is mutated from Ser (S) to Tyr (Y); and for the heavy chain variable region of humanized 5G1 1 antibody, the amino acid at position 24 is mutated from Phe (F) to Val (V), the amino acid at position 49 is mutated from Ala (A) to Gly (G), the amino acid at position 73 is mutated from Thr (T) to Asn (N), and the amino acid at position 83 is mutated from Thr (T) to Asn (N).
  • the amino acid at position 53 is mutated from Tyr (Y) to Lys (K); and for the heavy chain variable region of humanized 13C5, the amino acid at position 28 is mutated from Thr (T) to He (I), the amino acid at position 30 is mutated from Ser (S) to Arg (R), the amino acid at position 49 is mutated from Ser (S) to Ala (A), and the amino acid at position 94 is mutated from Tyr (Y) to Asp (D).
  • amino acid sequences of VH and VL of humanized 5G1 1 are provided as SEQ ID NOs:42 and 44, respectively; DNA sequences encoding the VH and VL of humanized 5G11 are provided as SEQ ID NOs: 41 and 43, respectively.
  • the amino acid sequences of VH and VL of humanized 13C5 are provided as SEQ ID NOs: 46 and 48, respectively); DNA sequences encoding the VH and VL of humanized 13C5 are provided as SEQ ID NOs: 45 and 47, respectively.
  • the amino acid sequences of the full light chain for humanized antibodies 5G11 and 13C5 are provided as SEQ ID NOs: 74 and 80, respectively.
  • the DNA sequences encoding the full length humanized 5G11 and 13C5 are provided as SEQ ID NOs: 73 and 79, respectively.
  • IgGl and IgG4 versions of the humanized 5G11 and 13C5 antibodies were produced.
  • the IgGl constant region carries D265A mutation (Clynes R, et al, Nature Medicine 6: 443-446 (2000)), while IgG4 constant region has F234A and L235A double mutation (Xu D, et al, Cellular Immunology 200: 16-26 (2000)).
  • the DNA and amino acid sequences for the full length IgGl heavy chain of humanized antibody 5Gl l-hIgGl are provided as SEQ ID NOs: 69 and 70, respectively.
  • the DNA and amino acid sequences for the full length IgG4 heavy chain of humanized antibody 5Gl l-hIgG4 are provided as SEQ ID NOs: 71 and 72, respectively.
  • the DNA and amino acid sequences for the full length IgGl heavy chain of humanized antibody 13C5-hIgGl are provided as SEQ ID NOs: 75 and 76, respectively.
  • the DNA and amino acid sequences for the full length IgG4 heavy chain of humanized antibody 13C5-hIgG4 are provided as SEQ ID NOs: 77 and 78, respectively.
  • DNA encoding humanized 5G11 and 13C5 antibody light chain and heavy chain was synthesized and cloned to the expression vector pcDNA3.1 (Invitrogen, CAT: #V-790). Freestyle 293 cells (200 mL at 10 6 /mL) were transfected with 100 ⁇ g of each of the humanized heavy and light chain expression plasmids and cultured for 6 days. The humanized antibody in the supernatant was then purified with Protein-G column (GE healthcare). [00112] The binding kinetics between PD-L1 and PD-L1 antibodies were measured by
  • Biacore analysis which was performed at 25°C on a Biacore3000 instrument and recorded with a data collection rate of 1 Hz.
  • Polyclonal rabbit anti-mouse IgG (GE, BR-1008-38) was diluted with 10 mM pH 5.0 sodium acetate and immobilized onto reference and experiment flow cells of a CM5 biosensor chip to around 15000RU using an amine coupling kit (GE, BR10050).
  • diluted test antibody 1.5 ⁇ g/mL
  • PD-L1 analyte series were prepared by diluting the stocks with running buffer to ⁇ followed by 2X serial dilution in the same buffer down to 0.78nM.
  • Analytes were injected in series over the reference and experiment flow cells for 3 minutes at a flow rate of 30 ⁇ / ⁇ .
  • Running buffer PBS with 0.05% P20
  • the biosensor surface was regenerated with 3 minutes injection of 10 mM pH1.7 Glycine-HCl buffer at a flow rate of 10 ⁇ / ⁇ .
  • binding responses obtained from the experimental biosensor surface were double referenced by subtracting simultaneously recorded responses from the reference surface followed by additional subtraction of responses from a single referenced running buffer sample.
  • association and dissociation rate constants (ka and kd) were determined simultaneously by fitting double-referenced sensorgrams of the entire titration series to Langmuir model (1 : 1) using Biaevaluation 4.0 software.
  • the binding affinity of anti-PD-Ll antibodies with human PD-L1 and cynomolgus PD-L1 (cyno-PD- Ll) are summarized in Table 4.
  • Example 3 ELISA based binding analysis of anti-PD-Ll antibodies
  • ELISA binding analyses were conducted based on human PD-Ll-mFc (for chimeric and humanized antibody detection) and PD-Ll-hFc protein (for hybridoma antibody detection).
  • 96-well plates (Costar, Cat No: 9018) were coated with 100 of 2 ⁇ PD-L1- mFc (Crownbio) in coating buffer PBS (Hyclone, Cat No:SH30256.01B) overnight at 4° C.
  • the wells were aspirated and non-specific binding sites were blocked by adding 200 ⁇ L ⁇ of blocking buffer (PBS with 1% (w/v) of bovine serum albumin (BSA, Roche, Cat No:738328)) and incubating for 1 hour at 37° C.
  • BSA bovine serum albumin
  • ELISA based ligand blockage analyses were conducted via blocking biotinylated human PD-Ll-mFc's binding to human PD-l-hFc.
  • PD-l-hFc antigen (Crownbio) was suspended in PBS buffer (2ug/ml, lOOul/well) and coated on the 96 well plate (Costar, Cat No: 9018) 4°C overnight.
  • the wells were aspirated and non-specific binding sites were blocked by adding 200 ⁇ L ⁇ of blocking buffer (PBS with 1% (w/v) of bovine serum albumin (BSA, Roche, Cat No:738328)) and incubating for 1 hour at 37° C.
  • BSA bovine serum albumin
  • the cell-associated fluorescence was then detected by flow cytometry analysis using FACS array.
  • the effects of anti-PD-Ll antibodies on PD-1 binding with PD-L1-293T were measured by the mean fluorescent intensity (MFI) of staining.
  • MFI mean fluorescent intensity
  • Inhibition of PD-1 binding by anti-PD-Ll hybridoma antibodies is shown in Figures 10a and 10b.
  • Inhibition of PD-1 binding by anti-PD-Ll chimeric antibodies is shown in Figure 11.
  • Inhibition of PD-1 binding by anti-PD-Ll humanized antibodies is shown in Figure 12.
  • the calculated IC50 for the hybridoma (Table 14), chimeric (Table 15), and humanized (Table 16) antibodies are shown in the tables below.
  • Example 5 Effect of anti-PD-Ll antibodies on T cell activation in a mixed lymphocyte reaction
  • a mixed lymphocyte reaction was employed to demonstrate the effect of murine (Figure 13a, 13b), chimeric ( Figure 14a, 14b), or humanized ( Figure 15a, 15b) anti-PD-Ll antibodies in blocking the PD-Ll /PD-1 pathway in lymphocyte effector cells.
  • T cells in the assay were tested for IFN- ⁇ and IL-2 secretion in the presence or absence of humanized anti-PD-Ll antibody.
  • Human CD4 T-cells were purified from human PBMC using a CD4 negative selection isolation kit (Mitenyi Biotech, cat# 130-091-155). Immature dendritic cells (DC) were derived from monocytes isolated from human PBMC using the Mo-DC Generation Toolbox (Miltenyi, Cat#l 30-093-568). The cells were cultured with Mo-DC Differentiation Medium for 7 days, and were then induced to be mature DC with Mo-Dc Maturation medium for 2 days. To set up the MLR, for each reaction, 10 5 purified T-cells and 10 4 allogeneic mature DC cells were added in a total volume of 200 ⁇ .
  • DC Immature dendritic cells
  • the testing antibody was assayed at different concentrations as shown in Figures 13a, 13b, 14a, 14b, 15a, and 15b (i.e., 20 ⁇ g/mL, 2 ⁇ g/mL, 0.2 ⁇ g/mL, 0.02 ⁇ g/mL, and 0.002 ⁇ g/mL). Either no antibody or an isotype control antibody was used as a negative control.
  • the cells were cultured for 5 days at 37 °C. On day 6 th , the levels of IFN- ⁇ and IL-2 in the culture medium were measured using the IL-2 ELISA kit (eBioscience) and hIFN- ⁇ ELISA kit (R&D, cat#DY285).
  • T regulatory cells are lymphocytes that suppress the immune response.
  • the effect of T regulatory cells on cytokine secretion of T effector cells in MLR was tested in the presence or absence of chimeric or humanized anti-PD-Ll antibodies.
  • T regulatory cells CD4+ CD25+
  • Immature dendritic cells DC were derived from monocytes isolated from human PBMC using the Mo-DC Generation Toolbox (Miltenyi, cat#l 30-093-568).
  • T regulatory cells were added into a mixed lymphocyte reaction containing purified CD4 + CD25 T cells and allogeneic dendritic cells in a 4: 1 ratio of CD4 + CD25 to T regulatory cells.
  • the reaction was added with lxlO A 5cells/well of CD4 + CD25 " cells, lxlO A 4cells/well of mDC, and 0.25x10 A 5 cells/well of CD4 CD25 cells.
  • Antibody was added to each reaction at a concentration of 10 ⁇ g/ml. Either no antibody or an isotype control antibody was used as a negative control.
  • the cells were cultured for 5 days at 37° C. On the 5 th day, 50 ⁇ medium was taken to detect IL-2 and IFN- gamma concentration. After supplementing each well with 50 ⁇ 1 culture medium, the cells were cultured for another 2 days before analyzed for cell proliferation by CTG (Promega, G7573). The levels of IFN- ⁇ and IL-2 in the culture medium were measured using a hIFN- ⁇ ELISA kit (R&D, cat#DY285) and IL-2 ELISA kit (eBioscience).
  • chimeric and humanized anti-PD-Ll antibodies ch-13C5-hIgGl, ch-13C5-hIgG4, hu-13C5-IgGl, hu-13C5-IgG4, ch- 5Gl l-IgGl , ch-5Gl l-IgG4, hu-5Gl 1-IgGl, and hu-5Gl l-IgG4, can reduce the inhibitory effect of Treg cells on the secretion of IFN- ⁇ by CD4 + CD25 " T effector cells, suggesting that anti-PD- Ll antibodies can modulate the immune suppression function of T regulatory cells.
  • Example 8 Human recall T cell response to tetanus toxoid challenge is enhanced by humanized anti-PD-Ll antibody
  • the human T-cell recall assay was employed using tetanus toxoid (TT) antigen to stimulate pre-existing memory T cells in the blood of healthy TT immunized donors.
  • TT tetanus toxoid
  • PBMC from recently [ ⁇ 1 year] TT immunized donors were plated into 96-well round bottom plates (costar, cat#3799) at 4 x 10 ⁇ 5 cells/well using RPMI1640 (Invitrogen, cat# A10491-01) supplemented with 80 U/ml penicillin, 80 g/ml streptomycin and 30% autologous serum, added with humanized 5G11 or 13C5 at various concentrations, and stimulated with 0. lug/ml SEB and ⁇ g/ml TT (Astarte Biologies). After co-culture for 7 days at 37°C, 5% C0 2 , the supernatant was harvested and the concentration of IFN- ⁇ was measured.
  • Figures 18a and 18b provide the results of the assay using PBMC from two separate donors.
  • the results of the study demonstrate that, compared to TT antigen alone, PD-L1 blockage with anti-PD-Ll antibody resulted in enhanced IFN- ⁇ secretion by memory T cells.
  • the humanized 5G11 and 13C5 antibody retained the functional activity of their parental antibodies during the humanization process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps et des fragments de liaison à l'antigène desdits anticorps, qui se lient à PD-L1, et des procédés d'utilisation desdits anticorps et fragments de liaison à l'antigène. La présente invention concerne par exemple des anticorps anti-PD-L1 humanisés et des procédés d'utilisation desdits anticorps.
EP15829791.1A 2014-08-05 2015-08-05 Anticorps anti-pd-l1 Active EP3177649B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014083715 2014-08-05
PCT/US2015/043723 WO2016022630A1 (fr) 2014-08-05 2015-08-05 Anticorps anti-pd-l1

Publications (3)

Publication Number Publication Date
EP3177649A1 true EP3177649A1 (fr) 2017-06-14
EP3177649A4 EP3177649A4 (fr) 2018-04-25
EP3177649B1 EP3177649B1 (fr) 2024-02-28

Family

ID=55264464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15829791.1A Active EP3177649B1 (fr) 2014-08-05 2015-08-05 Anticorps anti-pd-l1

Country Status (15)

Country Link
US (3) US10435470B2 (fr)
EP (1) EP3177649B1 (fr)
JP (2) JP6909153B2 (fr)
KR (1) KR102476226B1 (fr)
CN (4) CN118388646A (fr)
AU (2) AU2015301126B2 (fr)
CA (1) CA2956399A1 (fr)
ES (1) ES2987034T3 (fr)
IL (1) IL250415B (fr)
MX (2) MX390385B (fr)
NZ (1) NZ728749A (fr)
RU (1) RU2722212C9 (fr)
SG (2) SG10201901057UA (fr)
WO (1) WO2016022630A1 (fr)
ZA (1) ZA201700785B (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102375A1 (fr) 2018-11-14 2020-05-22 Regeneron Pharmaceuticals, Inc. Administration dans la lésion d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
WO2020176699A1 (fr) 2019-02-28 2020-09-03 Regeneron Pharmaceuticals, Inc. Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
WO2020180727A1 (fr) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
WO2021242728A1 (fr) 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer du col de l'utérus par administration d'un anticorps cemiplimab d'inhibiteur de pd-1
WO2022046833A1 (fr) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
WO2022051448A1 (fr) 2020-09-03 2022-03-10 Regeneron Pharmaceuticals, Inc. Procédés de traitement de la douleur cancéreuse par administration d'un inhibiteur de pd-1
WO2022204672A1 (fr) 2021-03-23 2022-09-29 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer chez des patients immunodéprimés ou immunovulnérables par administration d'un inhibiteur de pd-1
WO2023004287A1 (fr) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de point de contrôle et d'un virus oncolytique pour le traitement du cancer
WO2023159102A1 (fr) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Association d'inhibiteurs de point de contrôle et de virus oncolytique pour le traitement du cancer
WO2024223299A2 (fr) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Procédés de traitement du cancer par administration de compositions immunogènes et d'un inhibiteur de pd-1
WO2025080538A1 (fr) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer avec une combinaison d'un inhibiteur de pd1 et d'une immunocytokine ciblée

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (fr) 2008-12-09 2010-07-08 Genentech, Inc. Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN116333138A (zh) 2015-07-30 2023-06-27 宏观基因有限公司 Pd-1结合分子和其使用方法
WO2017077382A1 (fr) 2015-11-06 2017-05-11 Orionis Biosciences Nv Protéines chimères bifonctionnelles et leurs utilisations
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
WO2017196867A1 (fr) * 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anticorps anti-pd-l1
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
EP3454887B1 (fr) 2016-05-13 2021-01-20 Orionis Biosciences BV Interféron bêta mutant ciblé, et utilisations associées
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
CN106008714B (zh) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
CN109414500B (zh) * 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
WO2018029474A2 (fr) 2016-08-09 2018-02-15 Kymab Limited Anticorps anti-icos
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
EP3497129A1 (fr) * 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Méthodes thérapeutiques et de diagnostic du cancer
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
US11317611B2 (en) 2016-08-31 2022-05-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric PD-L1
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN108203720A (zh) * 2016-12-20 2018-06-26 上海生博生物医药科技有限公司 能靶向Her2并封闭PD-L1降低肿瘤免疫逃逸的CAR-T载体及其构建方法和应用
WO2018144999A1 (fr) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Interféron d'ingénierie ciblé et utilisations de ce dernier
EP3577133A1 (fr) 2017-02-06 2019-12-11 Orionis Biosciences NV Protéines chimériques ciblées et leurs utilisations
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CN107299110B (zh) * 2017-05-27 2019-11-22 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
CN107164410B (zh) * 2017-05-27 2019-09-03 上海优卡迪生物医药科技有限公司 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用
EP3630838A1 (fr) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Anticorps anti-pdl1 activables, et leurs procédés d'utilisation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN114632150B (zh) * 2017-11-02 2023-12-19 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (fr) 2017-12-19 2020-10-28 Kymab Limited Anticorps bispécifique pour icos et pd-l1
KR102311838B1 (ko) 2017-12-27 2021-10-14 주식회사 파멥신 항-pd-l1 항체 및 이의 용도
CN109970857B (zh) * 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN111542543B (zh) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 针对pd-l1的抗体及其变体
JP2021510078A (ja) * 2018-01-10 2021-04-15 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． Ｐｄ−ｌ１抗体、その抗原結合フラグメント、及びその製薬学的使用
WO2019148089A1 (fr) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Agents de liaison à xcr1 et leurs utilisations
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
EP3752528A4 (fr) * 2018-02-17 2021-11-03 Apollomics Inc. Traitement du cancer à l'aide d'une combinaison d'un modulateur de neutrophiles avec un modulateur de point de contrôle immunitaire
AU2019239850A1 (en) * 2018-03-19 2020-10-29 Lanier Biotherapeutics, Inc. High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (PD-L1) and uses thereof
AU2018418224B2 (en) * 2018-04-09 2025-04-17 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
WO2020041404A1 (fr) * 2018-08-23 2020-02-27 Macrogenics, Inc. Molécules se liant à pd-l1 et leur utilisation pour le traitement de maladies
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
MX2021005594A (es) 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
CN113164599B (zh) * 2018-12-24 2023-08-01 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
JP2022516072A (ja) * 2018-12-27 2022-02-24 ギガジェン，インコーポレイティッド 抗ｐｄ－ｌ１結合タンパク質およびその使用方法
US12421313B2 (en) 2019-01-25 2025-09-23 Chia Tia Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating tumor
WO2020156500A1 (fr) * 2019-01-31 2020-08-06 正大天晴药业集团股份有限公司 Utilisation d'un anticorps anti-pd-l1 dans le traitement du cancer de la tête et du cou
US20220175759A1 (en) * 2019-03-15 2022-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition for treating small cell lung cancer
BR112021023048A2 (pt) 2019-05-21 2022-04-19 Novartis Ag Moléculas de ligação a cd19 e usos das mesmas
CN111973739B (zh) * 2019-05-23 2024-02-13 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
CN113939315B (zh) * 2019-05-30 2024-04-02 正大天晴药业集团南京顺欣制药有限公司 治疗黑色素瘤的联用药物组合物
WO2020249003A1 (fr) * 2019-06-10 2020-12-17 Apollomics Inc. (Hangzhou) Protéine de fusion anticorps-interleukine et procédés d'utilisation
CN113905761A (zh) * 2019-06-10 2022-01-07 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
CN112168961A (zh) * 2019-07-03 2021-01-05 正大天晴药业集团南京顺欣制药有限公司 治疗结直肠癌的联用药物组合物
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
EP4023679A4 (fr) * 2019-08-30 2023-10-04 Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group Protéine de fusion ciblant pd-l1 et tgf-beta et son utilisation
US20220411513A1 (en) * 2019-09-30 2022-12-29 Harbour Biomed (Shanghai) Co., Ltd Anti-pd-l1 antigen binding protein and application thereof
US20230002492A1 (en) * 2019-11-08 2023-01-05 Simcere (Shanghai) Pharmaceutical Co., Ltd. Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
CN120437288A (zh) * 2019-12-24 2025-08-08 正大天晴药业集团南京顺欣制药有限公司 治疗卵巢癌的药物组合
IL272389A (en) * 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
EP4106813A4 (fr) 2020-02-21 2024-03-27 MacroGenics, Inc. Molécules de liaison à cd137 et leurs utilisations
CN113318226A (zh) * 2020-02-28 2021-08-31 正大天晴药业集团股份有限公司 抗pd-l1抗体联合放射性射线治疗肺癌的方法
AU2021250200A1 (en) 2020-04-02 2022-12-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antigen-binding polypeptide binding to CD47, and use thereof
CN115461079A (zh) * 2020-04-30 2022-12-09 正大天晴药业集团股份有限公司 用于治疗肾癌的联用药物
WO2021226984A1 (fr) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 Anticorps bispécifique tétravalent contre pd-1 et pd-l1
WO2021244551A1 (fr) 2020-06-02 2021-12-09 正大天晴药业集团股份有限公司 Composition pharmaceutique combinée d'inhibiteur de kinase c-met et d'anticorps anti-pd-l1
CN115698076A (zh) 2020-06-30 2023-02-03 正大天晴药业集团股份有限公司 用于治疗肿瘤的药物
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
EP4197554A4 (fr) * 2020-08-13 2024-09-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Médicament combiné pour le traitement d'un sarcome des tissus mous
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
MX2023008966A (es) 2021-02-07 2023-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticuerpo biespecifico.
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
EP4316518A4 (fr) 2021-03-29 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combinaison médicamenteuse d'un agoniste du récepteur 7 de type toll et d'un anticorps anti-pd-l1
WO2022243378A1 (fr) 2021-05-18 2022-11-24 Kymab Limited Utilisations d'anticorps anti-icos
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CA3225254A1 (fr) 2021-07-13 2023-01-19 BioNTech SE Agents de liaison multispecifiques contre cd40 et cd137 en polytherapie du cancer
WO2023001283A1 (fr) 2021-07-22 2023-01-26 正大天晴药业集团股份有限公司 Association médicamenteuse pour le traitement du cancer gastrique et/ou du cancer de la jonction œsogastrique
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
KR20240046526A (ko) 2021-08-05 2024-04-09 치아타이 티안큉 파마수티컬 그룹 주식회사 소세포폐암 치료용 약학적 조성물
CN117642181A (zh) * 2021-09-06 2024-03-01 正大天晴药业集团股份有限公司 用于治疗食管癌的药物组合
EP4389153A1 (fr) 2021-09-16 2024-06-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Conjugué anticorps anti-her3-médicament, composition de celui-ci et utilisation de celui-ci
US20240269278A1 (en) 2021-09-30 2024-08-15 Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group Anti-cd47 antibody for combined treatment of blood tumor
WO2023051926A1 (fr) 2021-09-30 2023-04-06 BioNTech SE Traitement impliquant un arn non immunogène pour vaccination antigénique et antagonistes liant l'axe pd-1
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (fr) 2021-11-09 2023-05-19 BioNTech SE Agoniste de tlr7 et combinaisons pour le traitement du cancer
WO2023098798A1 (fr) 2021-12-01 2023-06-08 正大天晴药业集团股份有限公司 Association de médicaments pour le traitement du cancer du poumon non à petites cellules
CN118871128A (zh) * 2022-03-18 2024-10-29 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-l1抗体的药物组合
EP4525991A1 (fr) 2022-05-18 2025-03-26 Kymab Limited Utilisations d'anticorps anti-icos
CN119278053A (zh) * 2022-06-02 2025-01-07 正大天晴药业集团股份有限公司 用于治疗子宫恶性肿瘤的药物组合
WO2024115725A1 (fr) 2022-12-01 2024-06-06 BioNTech SE Anticorps multispécifique contre cd40 et cd137 en polythérapie avec un anticorps anti-pd1 et une chimiothérapie
AU2023393653A1 (en) 2022-12-14 2025-05-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
EP4658310A1 (fr) 2023-01-30 2025-12-10 Kymab Limited Anticorps
WO2024228167A1 (fr) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Compositions liposomales de modulateur de cellules inkt et procédés d'utilisation
WO2025056180A1 (fr) 2023-09-15 2025-03-20 BioNTech SE Procédés de traitement faisant appel à des agents se liant à epcam et cd137 en combinaison avec des antagonistes de liaison à l'axe pd-1
CN117783521B (zh) * 2023-11-23 2025-03-04 中国农业科学院兰州兽医研究所 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒
WO2025121445A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
WO2025120867A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et anticorps anti-vegfr2
WO2025120866A1 (fr) 2023-12-08 2025-06-12 Astellas Pharma Inc. Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et agents stabilisant ou augmentant l'expression de cldn18.2
CN120865416A (zh) * 2025-09-28 2025-10-31 成都微芯新域生物技术有限公司 抗mica/b抗体及其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
CA2118508A1 (fr) 1992-04-24 1993-11-11 Elizabeth S. Ward Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2143491C (fr) 1994-03-01 2011-02-22 Yasumasa Ishida Nouveau peptide lie a l'apoptose humaine et adn codant ledit peptide
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1210428B1 (fr) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, recepteur de b7-4, et son utilisation
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
EP1266014A2 (fr) 2000-03-24 2002-12-18 Peter Kufer Polypeptides multifonctionnnels comportant un site de fixation d'un du complexe recepteur nkg2d
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
KR20030066657A (ko) 2000-11-15 2003-08-09 오노 야꾸힝 고교 가부시키가이샤 Ｐｄ-1 결손 마우스 및 그 용도
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ES2338534T3 (es) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
NZ538996A (en) 2002-10-31 2008-04-30 Genentech Inc Methods and compositions for increasing antibody production
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1587540B1 (fr) 2003-01-09 2021-09-15 MacroGenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1591527B1 (fr) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specifique a pd-1 humain
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005077981A2 (fr) 2003-12-22 2005-08-25 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP1810979B1 (fr) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. ANTICORPS IgG4 HUMAINS STABILISES
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN1296385C (zh) 2005-03-30 2007-01-24 王哲 抗猪生长激素单克隆抗体及制备方法及应用
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) * 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
SG10201706600VA (en) * 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
KR20080074220A (ko) 2005-12-08 2008-08-12 밀레니엄 파머슈티컬스 인코퍼레이티드 키나아제 억제 활성을 갖는 비시클릭 화합물
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
ATE552245T1 (de) 2006-05-15 2012-04-15 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
CN101104640A (zh) 2006-07-10 2008-01-16 苏州大学 抗人pd-l1单克隆抗体制备及应用
JP2009542810A (ja) 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
NZ720288A (en) 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
WO2008145142A1 (fr) 2007-05-31 2008-12-04 Genmab A/S Anticorps igg4 stables
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
AU2014201367B2 (en) 2007-06-18 2016-01-28 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2195347A1 (fr) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de traitement et de diagnostic de malignités hématologiques
CN101883845B (zh) * 2007-10-08 2015-06-10 英特瑞克斯顿股份有限公司 工程树突细胞及其在癌症治疗中的应用
AU2008312858A1 (en) * 2007-10-16 2009-04-23 Sbi Biotech Co., Ltd. Anti-BST2 antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
CA2735006A1 (fr) 2008-08-25 2010-03-11 Amplimmune, Inc. Antagonistes de pd-1 et leurs procedes d'utilisation
EP2342229A1 (fr) 2008-09-12 2011-07-13 ISIS Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
EP2342228B1 (fr) 2008-09-12 2017-09-06 Oxford University Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
ES2592216T3 (es) * 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
AU2013204861B2 (en) * 2008-09-26 2016-05-12 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
WO2010077634A1 (fr) * 2008-12-09 2010-07-08 Genentech, Inc. Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
HRP20161194T1 (hr) * 2009-03-10 2016-11-04 Biogen Ma Inc. Anti-bcma protutijela
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8389689B2 (en) 2009-10-28 2013-03-05 Janssen Biotech, Inc. Anti-GLP-1R antibodies and their uses
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
PL2536745T3 (pl) 2010-02-19 2017-01-31 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
EP2545078A1 (fr) 2010-03-11 2013-01-16 UCB Pharma, S.A. Anticorps pd-1
RU2012145183A (ru) 2010-03-29 2014-05-10 Займворкс, Инк. Антитела с повышенной или пониженной эффекторной функцией
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
AU2012250491A1 (en) 2011-05-02 2013-05-02 Ym Biosciences Australia Pty Ltd Multiple myeloma treatment
RU2616881C2 (ru) 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
CN102836441B (zh) * 2011-06-24 2019-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
EP2785375B1 (fr) * 2011-11-28 2020-07-22 Merck Patent GmbH Anticorps anti-pd-l1 et leur utilisation
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
ES2746103T3 (es) 2012-04-30 2020-03-04 Medimmune Llc Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2855528B1 (fr) 2012-05-31 2019-06-19 Genentech, Inc. Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
EP2869846A4 (fr) 2012-07-03 2016-01-13 Janssen Alzheimer Immunotherap Anticorps a-bêta contre des épitopes c-terminal et central
US9845356B2 (en) * 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
JP6461800B2 (ja) * 2012-10-04 2019-01-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
WO2014066834A1 (fr) * 2012-10-26 2014-05-01 The University Of Chicago Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
WO2014100490A1 (fr) 2012-12-19 2014-06-26 Adimab, Llc Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
MX364591B (es) 2013-03-15 2019-05-02 Regeneron Pharma Antagonistas de il-33 y usos de estos.
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
EP3322732A2 (fr) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102375A1 (fr) 2018-11-14 2020-05-22 Regeneron Pharmaceuticals, Inc. Administration dans la lésion d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
US12473364B2 (en) 2018-11-14 2025-11-18 Regeneron Pharmaceuticals, Inc. Intralesional administration of PD-1 inhibitors for treating skin cancer
EP4382168A2 (fr) 2018-11-14 2024-06-12 Regeneron Pharmaceuticals, Inc. Administration intra-lesionnelle d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
WO2020176699A1 (fr) 2019-02-28 2020-09-03 Regeneron Pharmaceuticals, Inc. Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
WO2020180727A1 (fr) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
US12187792B2 (en) 2019-03-06 2025-01-07 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
WO2021242728A1 (fr) 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer du col de l'utérus par administration d'un anticorps cemiplimab d'inhibiteur de pd-1
WO2022046833A1 (fr) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
US11932692B2 (en) 2020-09-03 2024-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating cancer pain by administering a PD-1 inhibitor
WO2022051448A1 (fr) 2020-09-03 2022-03-10 Regeneron Pharmaceuticals, Inc. Procédés de traitement de la douleur cancéreuse par administration d'un inhibiteur de pd-1
WO2022204672A1 (fr) 2021-03-23 2022-09-29 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer chez des patients immunodéprimés ou immunovulnérables par administration d'un inhibiteur de pd-1
WO2023004287A1 (fr) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de point de contrôle et d'un virus oncolytique pour le traitement du cancer
WO2023159102A1 (fr) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Association d'inhibiteurs de point de contrôle et de virus oncolytique pour le traitement du cancer
WO2024223299A2 (fr) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Procédés de traitement du cancer par administration de compositions immunogènes et d'un inhibiteur de pd-1
WO2025080538A1 (fr) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer avec une combinaison d'un inhibiteur de pd1 et d'une immunocytokine ciblée

Also Published As

Publication number Publication date
AU2015301126A1 (en) 2017-02-23
ZA201700785B (en) 2021-07-28
CA2956399A1 (fr) 2016-02-11
US20210371531A1 (en) 2021-12-02
SG11201700687TA (en) 2017-02-27
EP3177649B1 (fr) 2024-02-28
CN107001463A (zh) 2017-08-01
KR102476226B1 (ko) 2022-12-12
US10435470B2 (en) 2019-10-08
CN118388646A (zh) 2024-07-26
MX390385B (es) 2025-03-20
AU2021203593A1 (en) 2021-07-01
SG10201901057UA (en) 2019-03-28
JP6909153B2 (ja) 2021-07-28
CN110964109B (zh) 2023-08-25
MX2022002364A (es) 2022-04-06
BR112017002234A2 (pt) 2018-07-24
CN110964109A (zh) 2020-04-07
AU2015301126B2 (en) 2021-03-11
CN110964108A (zh) 2020-04-07
IL250415A0 (en) 2017-03-30
US11827707B2 (en) 2023-11-28
RU2722212C9 (ru) 2020-07-23
IL250415B (en) 2020-09-30
RU2017106804A (ru) 2018-09-06
KR20170039706A (ko) 2017-04-11
JP2017523786A (ja) 2017-08-24
US20170204184A1 (en) 2017-07-20
CN107001463B (zh) 2020-01-17
RU2722212C2 (ru) 2020-05-28
US11111300B2 (en) 2021-09-07
JP2020141672A (ja) 2020-09-10
CN110964108B (zh) 2023-07-07
NZ728749A (en) 2023-06-30
JP7144477B2 (ja) 2022-09-29
MX2017001597A (es) 2017-11-17
ES2987034T3 (es) 2024-11-13
WO2016022630A1 (fr) 2016-02-11
RU2017106804A3 (fr) 2019-08-27
EP3177649A4 (fr) 2018-04-25
AU2021203593B2 (en) 2024-04-18
US20200031935A1 (en) 2020-01-30
NZ766660A (en) 2024-02-23

Similar Documents

Publication Publication Date Title
US11827707B2 (en) Anti PD-L1 antibodies
US11560429B2 (en) Anti PD-1 antibodies
HK1242960B (en) Anti-pd-1 antibodies
BR112017002234B1 (pt) Anticorpo isolado que se liga a pd-l1 ou fragmento do mesmo, uso do anticorpo ou fragmento, composição, polinucleotídeo isolado e vetor de expressão
BR122020026802B1 (pt) Anticorpo isolado que se liga a pd-l1 ou fragmento do mesmo, uso do anticorpo ou fragmento, composição, polinucleotídeo isolado e vetor de expressão

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20171117BHEP

Ipc: A61K 47/68 20170101ALI20171117BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180328

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/68 20170101ALI20180322BHEP

Ipc: C07K 16/28 20060101AFI20180322BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1239716

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191008

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101AFI20201015BHEP

Ipc: A61P 33/00 20060101ALI20201015BHEP

Ipc: A61P 31/00 20060101ALI20201015BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20210624BHEP

Ipc: A61P 35/02 20060101ALI20210624BHEP

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: APOLLOMICS INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015087730

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07K0016280000

Ipc: A61P0031040000

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0016280000

Ipc: A61P0031040000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/68 20170101ALI20230802BHEP

Ipc: A61P 33/12 20060101ALI20230802BHEP

Ipc: A61P 33/06 20060101ALI20230802BHEP

Ipc: C07K 16/28 20060101ALI20230802BHEP

Ipc: A61P 35/02 20060101ALI20230802BHEP

Ipc: A61P 35/00 20060101ALI20230802BHEP

Ipc: A61P 31/06 20060101ALI20230802BHEP

Ipc: A61P 33/00 20060101ALI20230802BHEP

Ipc: A61P 31/16 20060101ALI20230802BHEP

Ipc: A61P 31/12 20060101ALI20230802BHEP

Ipc: A61P 31/10 20060101ALI20230802BHEP

Ipc: A61P 31/04 20060101AFI20230802BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230925

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015087730

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240528

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240528

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240528

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240529

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1660698

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240628

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2987034

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20241113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015087730

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20241129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240228

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20240831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250926

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250820

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250825

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250820

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250829

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250901

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250820

Year of fee payment: 11